Breast Cancer
Conference Coverage
OlympiAD: No statistically significant boost in OS with olaparib in HER2-negative mBC
CHICAGO – In the final analysis, median OS was 2.2 months longer for olaparib monotherapy versus physician’s choice of chemotherapy in patients...
Conference Coverage
Can cN0 and pCR limit axillary surgery in some breast cancer patients?
CHICAGO – Investigators question whether nodal negativity after neoadjuvant chemotherapy could limit need for axillary surgery in certain breast...
Original Report
Analgesic management in radiation oncology for painful bone metastases
From the Journals
Sarcopenia, body fat linked with mortality in nonmetastatic breast cancer
Low muscle mass was independently associated with a 41% increase in risk for overall mortality in an observational study of 3,241 women diagnosed...
From the Journals
21-gene assay predicts survival in male and female breast cancer
An analysis of genomic and survival data shows that survival of men with breast cancer is lower than that of women with similar clinical features...
Conference Coverage
Think about breast cancer surveillance for transgender patients
CHICAGO - In transgender men, breast cancer can occur years after mastectomy.
Conference Coverage
Over one-third report financial burden from breast cancer treatment
CHICAGO – Out-of-pocket costs pose a financial burden for women weighing breast cancer surgery, but cost transparency is elusive.
Conference Coverage
HDAC inhibition may boost immune therapy efficacy in breast cancer
ORLANDO – Entinostat and nivolumab with or without ipilimumab showed encouraging activity in early results from a phase 1 trial of patients with...
From the Journals
Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer
Using a PARP inhibitor as a radiosensitizer in treatment of women with inflammatory breast cancer was associated with late grade 3 adverse events...
From the Journals
Accelerated breast irradiation advocated by ASTRO guideline
Expanded patient population eligible for whole breast hypofractionated radiation therapy in updated ASTRO guideline.
Conference Coverage
Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer
The in vitro success has launched a phase 2 trial recruiting 152 patients.